Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ILX651 · 3 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| ILX651 | DRUG | - |
Inclusion Criteria: * Histologically confirmed locally advanced or metastatic NSCLC previously treated with 2 prior chemotherapy regimens (not including prior adjuvant therapy for stage I or II disease). * Disease recurrence or progression after prior therapy with a platinum-based and a taxane-base...
ILX651 is an investigational small molecule being studied for the treatment of several advanced solid tumors, including non-small-cell lung carcinoma, hormone-refractory prostate cancer, and melanoma. It is being developed by Sanofi (SNY) and has completed Phase 2 clinical trials in these indications.
ILX651 is a small molecule oncology drug. Its specific molecular target has not been disclosed in the available clinical trial information. It is being evaluated for its antitumor activity in patients with advanced cancers such as melanoma, non-small-cell lung carcinoma, and hormone-refractory prostate cancer.
ILX651 is being developed by Sanofi, a global pharmaceutical company listed on the stock exchange under the ticker SNY. Sanofi is conducting clinical research to evaluate the safety and efficacy of ILX651 in patients with advanced solid tumors.
ILX651 is in Phase 2 clinical development. It has completed Phase 2 trials in patients with inoperable locally advanced or metastatic melanoma, locally advanced or metastatic non-small-cell lung carcinoma, and hormone-refractory prostate cancer previously treated with docetaxel. It is not approved by the FDA.
ILX651 has completed three Phase 2 clinical trials in the United States. These include NCT00068211 in melanoma, NCT00078455 in non-small-cell lung carcinoma, and NCT00082134 in hormone-refractory prostate cancer. The prostate cancer trial enrolled 40 patients who had previously been treated with docetaxel.
ILX651 is a distinct investigational drug candidate. No alternative names for ILX651 have been reported in the clinical trial records. It is being studied as a monotherapy in uncontrolled, non-randomized trials for advanced solid tumors.